HC Wainwright Has Weak Forecast for Gossamer Bio Q2 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – HC Wainwright lowered their Q2 2026 earnings estimates for Gossamer Bio in a report issued on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.09) per share for the quarter, down from their previous estimate of ($0.05). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.42) EPS, Q3 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.20) EPS.

Several other analysts have also recently issued reports on GOSS. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Weiss Ratings cut shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. The Goldman Sachs Group cut shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Oppenheimer reduced their target price on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $1.00 target price (down from $6.00) on shares of Gossamer Bio in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $5.00.

Gossamer Bio Stock Performance

Shares of GOSS opened at $0.22 on Thursday. The stock has a market capitalization of $51.14 million, a PE ratio of -0.28 and a beta of 2.15. Gossamer Bio has a 1 year low of $0.16 and a 1 year high of $3.87. The company’s 50-day simple moving average is $0.35 and its 200-day simple moving average is $1.71.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Monday, May 18th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $16.96 million for the quarter, compared to analyst estimates of $4.67 million.

Institutional Trading of Gossamer Bio

Several hedge funds have recently added to or reduced their stakes in the company. MB Generational Wealth LLC acquired a new stake in Gossamer Bio during the third quarter worth approximately $3,721,000. Jones Financial Companies Lllp raised its holdings in Gossamer Bio by 136.7% during the third quarter. Jones Financial Companies Lllp now owns 17,360 shares of the company’s stock worth $47,000 after purchasing an additional 10,027 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in Gossamer Bio during the third quarter worth approximately $48,000. Fullcircle Wealth LLC acquired a new stake in Gossamer Bio during the third quarter worth approximately $58,000. Finally, SG Americas Securities LLC acquired a new stake in Gossamer Bio during the third quarter worth approximately $56,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Trending Headlines about Gossamer Bio

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on Gossamer Bio and maintained a $5.00 price target, indicating meaningful upside relative to the current share price. Benzinga article
• Neutral Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Berger Montague, the Schall Law Firm, Pomerantz, and others, issued reminders about the June 1, 2026 lead plaintiff deadline for the class action lawsuit covering investors who bought shares between June 16, 2025 and February 20, 2026. These notices keep the litigation story in focus. Berger Montague reminder article
• Neutral Sentiment: Additional “deadline alert” announcements from other firms are largely procedural and mostly reinforce that shareholder litigation is ongoing rather than adding new operational news. Frank R. Cruz deadline alert article
• Negative Sentiment: The core lawsuit centers on allegations that Gossamer’s executives concealed risks tied to the PROSERA trial outcome, including the study failing to meet its primary endpoint. That kind of clinical setback can raise concerns about future pipeline value and prolong uncertainty for shareholders. HBSS article

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.